Application of ICOSL agonist in preparation of vaccine
Through the COVID-19 nanoparticle vaccine coupled to ICOS protein and RBD protein, targeting the ICOSL signaling pathway, the problem of insufficient effectiveness of existing vaccines in immunodeficient populations has been solved, significantly improving the number of antibody response and secretion cells, and showing more Strong protection effect.
Patent Information
- Application Number
- CN202410959752.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-07-17
AI Technical Summary
Existing vaccines are not effective in immunodeficient or inadequate populations, especially in follicular-assisted T-cell defect conditions, making it difficult to effectively activate B cells and promote antibody responses.
Through the COVID-19 nanoparticle vaccine coupled to ICOS protein and RBD protein, it targets the ICOSL signaling pathway, activates ICOSL molecules, promotes B cell proliferation and antibody secretion, and improves the immune effect of the vaccine.
Under TFH defect conditions, the nanoparticle vaccine coupled to ICOS significantly improves the differentiation and proliferation of antibody-secreting cells, showing a stronger protective effect, especially for immunodeficient people.
Smart Images

Figure CN119015407A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of immunology technology, and more specifically, to the use of ICOSL agonists in the preparation of vaccines. Background Art
[0002] Vaccination is one of the important means of prevention and control when infectious diseases are spreading or breaking out. Vaccination can stimulate the immune system to produce protective immunity, prevent pathogen infection, inhibit the occurrence and spread of diseases, reduce morbidity and mortality, reduce the number of infections and reduce the negative impact on social life.
[0003] After a person is vaccinated, the vaccine is first recognized and taken up by antigen-presenting cells (APC) in the immune system, such as dendritic cells (DC) or macrophages. After processing, the antigen peptides are presented to T lymphocytes or B lymphocytes. Among them, B lymphocytes differentiate into germinal center B cells (GCB) to form germinal centers after receiving antigen stimulation, and then undergo antibody affinity maturation with the help of T helper cells, and continue to differentiate into plasma cells and memory B cells. Activated CD4 T lymphocytes differentiate into a special group of subpopulations, which are follicular helper CD4 T (T follicular helper, T FH ) cells, which can interact with GCB cells to regulate the maturation of GCB cells and the production of high-affinity neutralizing antibodies.
[0004] T FH The cells express a variety of important molecules that interact with B cells, such as CD40L, IL-21, IL-4, ICOS, etc. These cytokines also play a role in promoting B cell proliferation, activation, and differentiation during B cell activation. Especially in immunodeficient / insufficient populations, including those whose immune system function is impaired due to genetic or acquired diseases, and individuals whose immune function is insufficient / decreased due to aging, therefore, the development of targeted vaccines for immunodeficient / insufficient populations is of great practical significance.
[0005] In recent years, the emergence of nanoparticle vaccines has provided new strategies and new ideas for breaking through the limitations of traditional vaccines. Nanoparticle vaccines have become a hot topic in the field of vaccine research and development in recent years due to their unique design and efficient antigen presentation capabilities. Ferritin is a natural protein that exists in almost all organisms and can self-assemble into a 24-mer nanoparticle structure. The rich surface and highly ordered repetitive symmetrical structure of ferritin nanoparticles make them ideal for antigen delivery, helping to induce efficient immune responses and improve the efficacy of vaccines. Related studies have developed influenza virus, new coronavirus, and nasopharyngeal carcinoma virus vaccines based on ferritin nanoparticles, all of which have now entered the clinical trial stage.
[0006] Therefore, it is of great practical significance to develop personalized vaccines for people with immune deficiency / insufficiency to improve the effectiveness of vaccines. Summary of the invention
[0007] The purpose of the present invention is to overcome the deficiencies of the prior art and provide an application of an agonist of ICOSL in the preparation of a vaccine.
[0008] The first object of the present invention is to provide use of an agonist of ICOSL protein in the preparation of a vaccine or a vaccine adjuvant.
[0009] The second object of the present invention is to provide use of an agonist of ICOSL protein in the preparation of a vaccine or a synergist of a vaccine adjuvant.
[0010] The third object of the present invention is to provide a vaccine or adjuvant containing an agonist of ICOSL protein.
[0011] The fourth object of the present invention is to provide an agonist and antigen composition of ICOSL protein for use in preparing a vaccine.
[0012] A fifth object of the present invention is to provide an antigen with enhanced immunogenicity.
[0013] The sixth object of the present invention is to provide an antigen of the new coronavirus with enhanced immunogenicity.
[0014] The seventh object of the present invention is to provide an HIV virus antigen with enhanced immunogenicity.
[0015] The eighth object of the present invention is to provide the use of any of the antigens in the preparation of vaccines
[0016] The ninth object of the present invention is to provide a vaccine with enhanced immunogenicity.
[0017] In order to achieve the above object, the present invention is implemented by the following technical solutions:
[0018] The present invention found that in follicular helper T cells (TFH ) deficiency conditions, the COVID-19 nanoparticle vaccine that is coupled with ICOS protein and RBD protein at the same time can activate ICOSL (Inducible T cell co-stimulator ligand, NCBI Ref: NP_NP_001269979.1) molecules, which can effectively promote antibody response and differentiation and proliferation of antibody-secreting cells. It also further clarifies the specific molecular mechanism by which ICOSL protein regulates B cell response and its role as a new adjuvant target for anti-COVID or HIV vaccines under conditions of immune deficiency or insufficiency. By coupling ICOS protein molecules to target the ICOSL signaling pathway, a stronger protective effect is demonstrated in vaccines against COVID-19 and HIV viruses.
[0019] The present invention is intended to protect the following applications:
[0020] Use of an agonist of ICOSL protein in the preparation of a vaccine or a vaccine adjuvant.
[0021] Use of ICOSL protein agonists in the preparation of vaccines or vaccine adjuvant enhancers.
[0022] Preferably, the agonist of ICOSL is ICOS protein (NCBI Ref: NP_036224.1).
[0023] Preferably, the vaccine is for immunodeficient people and / or people with insufficient immune function and / or decreased immune function.
[0024] Preferably, the vaccine is against T FH People with cell defects.
[0025] Preferably, the potentiator improves the immune effect of the vaccine.
[0026] Preferably, the potentiator promotes the antibody response and / or the differentiation and / or proliferation of antibody secreting cells.
[0027] Therefore, a vaccine or adjuvant containing an agonist of ICOSL is also desired.
[0028] Preferably, the agonist of ICOSL protein is ICOS protein.
[0029] And, the use of ICOSL protein agonist and antigen composition in the preparation of vaccines.
[0030] Preferably, the agonist of ICOSL protein is ICOS protein.
[0031] Specifically, the present invention claims protection for the following products:
[0032] An antigen with enhanced immunogenicity, wherein the antigen is obtained by combining component 1 and component 2 through spontaneous chemical bonds of Gv-Sd, wherein component 1 is a mixture of a protein having an amino acid sequence such as SEQ ID NO: 12 and a fusion protein containing an immunogen, wherein the fusion protein containing the immunogen is a protein expressed by fusion of an immunogen and a SD peptide segment, and the amino acid sequence of the SD peptide segment is shown in SEQ ID NO: 8; and component 2 is a protein having an amino acid sequence such as SEQ ID NO: 5.
[0033] An antigen of a new coronavirus with enhanced immunogenicity, wherein the antigen is obtained by combining component 1 and component 2 through spontaneous chemical bonds of Gv-Sd, wherein component 1 is a mixture of a protein with an amino acid sequence such as SEQ ID NO: 12 and a protein with an amino acid sequence such as SEQ ID NO: 9; and component 2 is a protein with an amino acid sequence such as SEQ ID NO: 5.
[0034] An antigen of HIV virus with enhanced immunogenicity, wherein the antigen is obtained by combining component 1 and component 2 through spontaneous chemical bonds of Gv-Sd, wherein component 1 is a mixture of a protein with an amino acid sequence such as SEQ ID NO: 12 and a protein with an amino acid sequence such as SEQ ID NO: 18; and component 2 is a protein with an amino acid sequence such as SEQ ID NO: 5.
[0035] Further claimed is the use of any of said antigens in the preparation of a vaccine.
[0036] And a vaccine with enhanced immunogenicity, which is prepared using any of the antigens.
[0037] Compared with the prior art, the present invention has the following beneficial effects:
[0038] The present invention found that in follicular helper T cells (T FH ) deficiency conditions, ICOS acts as an agonist of ICOSL, and the nanoparticle vaccine coupled with the agonist of ICOSL can activate the ICOSL molecule, directly act on ICOSL to promote B cell proliferation, the expression of anti-apoptosis related genes, and can efficiently promote antibody response and differentiation and proliferation of antibody-secreting cells; a vaccine coupled with ICOS is prepared, and the ICOSL signaling pathway is targeted by the coupled ICOS molecule, which shows a stronger protective effect in the vaccine against the new coronavirus and HIV virus, especially for people with immune deficiency / insufficiency. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1The figure shows the construction of SARS-CoV-2 nanoparticle vaccine; A is a schematic diagram of RBD coupled with CD40, IL-21, ICOS and other molecules on the same nanoparticle surface, where GV / SD can undergo self-catalytic coupling reaction; B is the expression analysis of purified Ferritin, RBD, CD40, IL-21, and ICOS proteins, and the confirmation of successful coupling of molecules with Ferritin by protein gel, *RBD coupled with Ferritin**CD40L coupled with Ferritin***IL-21 coupled with Ferritin****ICOS coupled with Ferritin; C is a scanning electron microscope analysis of the morphology and size uniformity of the assembled nanoparticles. .
[0040] Figure 2 Conjugated ICOS can enhance the efficacy of SARS-CoV-2 RBD nanoparticle vaccine in T FH Antibody immune responses in CD4-deficient mice; A is CD4 cre Bcl6 fl / fl Mouse immunization strategy; B is the ELISA test of RBD-specific IgG titer in mouse plasma at 6 weeks after immunization; C is the ELISA test of RBD-specific IgA titer in mouse plasma at 6 weeks after immunization; D is the ELISA test of RBD-specific IgG titer in mouse plasma at each time point.
[0041] Figure 3 ICOS-coupled SARS-CoV-2RBD nanoparticles induce high-quality antibody production in TFH-deficient mice; A is an ELISA combined with 7M urea elution to analyze the content of high-affinity antibodies in plasma 6 weeks after immunization; B is a pseudovirus neutralization test to test the neutralizing active antibody titer contained in the mouse plasma 6 weeks after immunization.
[0042] Figure 4 Immunization of CD4 with ICOS-RBD nanoparticle vaccine Cre Bcl6 fl / fl The number of B cells and antibody-secreting cells in mice increased significantly after 14 days of immunization; A is CD4 Cre Bcl6 fl / fl Mouse CD3 + T quantity and B220 + B is the flow cytometric analysis of CD4 Cre Bcl6 fl / fl Mouse CD3 + T number and ratio analysis, C is CD4 Cre Bcl6 fl / fl Mouse B220 + B is the number and proportion analysis; D is the CD4Cre Bcl6 fl / fl Analysis of the number and proportion of GL7+GC B cells in the spleen of mice; E is the CD4 Cre Bcl6 fl / fl Analysis of the number and proportion of CD138+ plasmablasts in mouse spleen; F is the number of CD4 Cre Bcl6 fl / fl Analysis of the number and proportion of total B cells in mouse spleen; G is CD4 Cre Bcl6 fl / fl Analysis of the number and proportion of memory B cells in mouse spleen; H is the CD4 ELIspot detection after 10 weeks of immunization Cre Bcl6 fl / fl The number of RBD-specific antibody-secreting B cells in the mouse bone marrow.
[0043] Figure 5 A shows that ICOS significantly enhanced B cell responses; A shows that purified ICOS protein binds to ICOSL on B cells (red); B shows that ICOSL blockade significantly inhibited the production of SARS-CoV-2RBD-specific IgG antibodies induced by ICOS-RBD nanoparticles; C shows that the percentage of plasmablasts (B220+CD138+) induced by ICOS-RBD nanoparticles decreased after treatment with ICOSL antibody blocker.
[0044] Figure 6 ICOS nanoparticles can promote the survival and proliferation of primary B cells in vitro; A shows that ICOS can bind to 293T cells expressing ICOSL; B to D show the detection of ICOS nanoparticles stimulating mouse spleen B cells in vitro, including in vitro cell proliferation counting analysis (B), BrdU insertion experiment cell cycle detection analysis (C), AnnexinV / PI staining cell apoptosis flow cytometry analysis (D).
[0045] Figure 7 Analysis of the molecular mechanism of ICOS activating B cells; A shows that after ferritin (HPF) and ICOS nanoparticles were treated in vitro for 2 hours with primary isolated mouse B cells, PKC, AKT, and NF-κB phosphorylation modification and total protein expression levels were detected by WB; B shows that after ferritin (HPF) and ICOS nanoparticles were treated in vitro for 48 hours with primary isolated mouse B cells, total RNA was extracted and the expression levels of cell cycle and apoptosis-related genes were detected by qPCR.
[0046] Figure 8Schematic diagram of vaccination, serum collection and intranasal virus infection of Cd4cre Bcl6fl / fl mice. A: Mice were immunized with HPF, RBD-HPF and ICOS-RBD-HPF vaccines at weeks 0 and 2, and infected intranasally with Omicron EG.5 strain at week 4. They were euthanized on day 5 after infection and subsequently analyzed; B: ELISA for RBD-specific antibody IgG titers in sera collected from immunized mice at week 4, measured by serial dilution and expressed as the reciprocal of the endpoint serum dilution, n = 4-5 per group; C: On day 5 after infection, the lungs of mice were collected, and the number of viral RNA copies in the lungs of each mouse was measured by qRT-PCR and plotted as log10 copies per ml; D and E: On day 5 after infection, the lungs of mice were collected, and H&E staining and immunohistochemical staining showed pathological changes and viral replication in the lungs of mice, and the scale bar is 100μm.
[0047] Fig. 9 The figure is an evaluation of the immune effect of ICOS-coupled HIV nanoparticle vaccine (MD39) under immune deficiency conditions; A is a schematic diagram of the assembly of ICOS-coupled HIV nanoparticle vaccine; B and C are Coomassie blue staining (B) and WB (C, anti-HIVgp120) confirming the successful assembly of ICOS HIV nanoparticle vaccine *MD39**MD39 after Ferritin coupling***ICOS after Ferritin coupling; D. Schematic diagram of the immunization strategy for CD4CreBcl6fl / fl mice; E and F are ELISA tests for HIV-specific IgG antibody titers in mice at the fourth week of immunization (E), and their changes over time (F); G is ELIA combined with 7M urea elution to detect the proportion of HIV-specific high-affinity IgG content; H is ELISpot detection of the number of HIV env-specific antibody-secreting cells in the bone marrow of mice immunized for 8 weeks. DETAILED DESCRIPTION
[0048] The present invention is further described in detail below in conjunction with the accompanying drawings and specific examples of the specification. The examples are only used to explain the present invention and are not used to limit the scope of the present invention. The test methods used in the following examples are conventional methods unless otherwise specified; the materials and reagents used are reagents and materials that can be obtained from commercial channels unless otherwise specified.
[0049] Tris-NaCl buffer: 20mM Tri-HCl 50mM NaCl
[0050] Example 1 Preparation of COVID-19 Nanoparticle Vaccine
[0051] 1. Experimental Methods
[0052] Helicobacter pylori ferritin (HPF) is unlikely to induce autoantibodies, so HPF is used as the core of the nanoparticle vaccine. The surface of ferritin nanoparticles can be coupled to multiple molecules at the same time. The GvoTagOpti-SdCatcher (Gvo-SD) system is used to bind T FH Important cellular functional proteins (CD40L, ICOS, and IL-21) were displayed on the same ferritin nanoparticles together with the codon-optimized SARS-CoV-2 RBD. Figure 1 A in the figure is a schematic diagram), CD40L-RBD nanoparticle vaccine, ICOS-RBD nanoparticle vaccine and IL12-RBD nanoparticle vaccine against SARS-CoV-2 were constructed.
[0053] The specific method is:
[0054] 1. Construction of recombinant protein expression plasmid
[0055] The DNA encoding Gvo (the nucleotide sequence of which is shown in SEQ ID NO: 1, and the amino acid sequence encoded by it is shown in SEQ ID NO: 2) was connected with the DNA sequence of HPF (the nucleotide sequence of which is shown in SEQ ID NO: 3, and the amino acid sequence encoded by it is shown in SEQ ID NO: 4) to obtain Gvo-HPF (the nucleotide sequence of which is shown in SEQ ID NO: 5, and the amino acid sequence encoded by it is shown in SEQ ID NO: 6), and a 6×His tag was introduced at the C-terminus to obtain Gvo-HPF-His, which was digested with NcoI and XhoI and connected to the pET-28a vector using the homologous recombination cloning method to obtain the plasmid pET28a-Gvo-HPF-His.
[0056] The DNA encoding SD (the nucleotide sequence of which is shown in SEQ ID NO: 7 and the amino acid sequence encoded by it is shown in SEQ ID NO: 8) was connected to the RBD sequence, ICOS sequence and IL-21 sequence, respectively, to obtain RBD-SD (the nucleotide sequence of which is shown in SEQ ID NO: 9 and the amino acid sequence encoded by it is shown in SEQ ID NO: 10), ICOS-SD (the nucleotide sequence of which is shown in SEQ ID NO: 11 and the amino acid sequence encoded by it is shown in SEQ ID NO: 12) and IL-21-SD (the nucleotide sequence of which is shown in SEQ ID NO: 13 and the amino acid sequence encoded by it is shown in SEQ ID NO: 14). NO: 14), and a 6×His tag was further introduced at the C-terminus to obtain RBD-SD-His, ICOS-SD-His and IL-21-SD-His, which were then double-digested with XhoI and XbaI and connected to the pCDNA3.1(+) vector using T4 enzyme to obtain plasmids pcDNA3.1-RBD-SD-His and pET28a-ICOS-SD-His; double-digested with NcoI and XhoI and connected to the pET28a vector using enzyme to obtain pET28a-IL-21-SD-His.
[0057] Since CD40L is a type II membrane protein, the SD sequence was genetically fused to the N-terminus of CD40L and downstream of the secretory signal peptide (SP) to obtain SD-CD40L (the nucleotide sequence is shown in SEQ ID NO: 15, and the amino acid sequence encoded by it is shown in SEQ ID NO: 16), and a 6×His tag was introduced at the C-terminus, SD-CD40L-His, double-digested with NcoI and XhoI, and connected to the pET28a vector using T4 enzyme to obtain the plasmid pET28a-SD-CD40L-His.
[0058] 2. Expression of Recombinant Protein
[0059] The above sequenced recombinant eukaryotic expression plasmid pcDNA3.1-RBD-SD-His was transiently transfected into 293F cells in good growth state, and 500 mL of cell resuspension was transfected to prepare transfection mixture (plasmid premix: Opti serum-free medium 20 mL + recombinant eukaryotic expression plasmid pcDNA3.1-RBD-SD-His 0.625 mg; PEI MAX premix: Opti serum-free medium 20 mL + PEI 1.875mL), invert several times, mix well and let stand for 5 minutes, then add PEI MAX premix to plasmid premix, mix gently and let stand for 15 minutes to obtain transfection system; slowly add 40mL transfection system to the cell resuspension, and shake the suspension cell culture bottle slowly and continuously during the addition process. After the transfection system is completely added, culture the cells under normal conditions; 5 days after transfection, collect the cells in a 50mL centrifuge tube, centrifuge at room temperature at 10000rpm for 10 minutes, transfer the supernatant after centrifugation to a new 50mL centrifuge tube, and the target protein (RBD-SD-His) is in the cell supernatant.
[0060] The above-mentioned correctly sequenced recombinant prokaryotic expression plasmids pET28a-SD-CD40L-His, recombinant prokaryotic expression plasmids pET28a-ICOS-SD-His and recombinant prokaryotic expression plasmids pET2a-IL-21-SD-His were transformed into Rosetta (DE3) competent expression strains, and the activated bacterial solution was inoculated into 1L TB resistance medium, and cultured on a shaking table at 37°C, 220rpm for about 4h until the absorbance OD600 reached 0.5; IPTG inducer with a final concentration of 1mM was added, and the culture was induced on a shaking table at 16°C, 220rpm for 16-24h; the bacterial solution was collected, centrifuged at 4000rpm for 10min, the supernatant was discarded, and 50mL The bacteria were resuspended in Tris-NaCl buffer; the resuspended bacteria were crushed under high pressure; the crushed bacterial solution was centrifuged at 4°C 12000rpm for 30min to remove the insoluble precipitate. The target proteins (SD-CD40L-His, ICOS-SD-His and IL-21-SD-His) were in the supernatant of the lysate.
[0061] The correctly sequenced recombinant prokaryotic expression plasmid pET28a-Gvo-HPF-His was transformed into the Rosetta (DE3) competent expression strain, and the activated bacterial solution was inoculated into 1L TB resistance medium, and cultured on a shaking table at 37°C, 220rpm for about 4h until the absorbance OD600 reached 0.5; IPTG inducer with a final concentration of 1mM was added, and the culture was induced on a shaking table at 16°C, 220rpm for 16-24h; the bacterial solution was collected, centrifuged at 3000rpm for 10min, the bacteria were collected, ultrasonically broken, the precipitate was discarded by centrifugation, the retained supernatant was diluted to a concentration of 1μg / μL, and then the supernatant was placed in a 70°C water bath, taken out after 15min, and the E. coli protein precipitate was removed by centrifugation, and the target protein (Gvo-HPF-His) was in the supernatant.
[0062] 3. Purification of recombinant protein
[0063] Since the recombinant protein expression plasmids all introduced 6×His tags at the C-terminus, the His tags were combined with nickel ion affinity columns and then competitively eluted with imidazole to purify the target proteins (RBD-SD-His, Gvo-HPF-His, SD-CD40L-His, ICOS-SD-His and IL-21-SD-His). Take 3mL of Ni-NTA column preserved with ethanol, remove the plug at the bottom of the gravity column, wash away the ethanol with 5 column volumes of deionized water, and then balance the gravity column with 5 column volumes of Tris-NaCl buffer; add the treated sample to the gravity column, cover the gravity column, and incubate on a shaker for 1 hour; wash with 5 column volumes of Tris-NaCl buffer containing 20mM imidazole, and then elute the target protein with Tris-NaCl buffer containing 100, 200 and 500mM imidazole respectively; and use SDS-PAGE to detect the purity of the target protein.
[0064] Subsequently, the target proteins (RBD-SD-His, Gvo-HPF-His, SD-CD40L-His, ICOS-SD-His and IL-21-SD-His) were further purified by size exclusion chromatography (SEC) and concentrated by ultrafiltration centrifugation. The supernatant was collected and the expression of the target proteins (RBD-SD-His, Gvo-HPF-His, SD-CD40L-His, ICOS-SD-His and IL-21-SD-His) was identified by Coomassie Brilliant Blue staining.
[0065] 4. Preparation of Nanoparticle Vaccines
[0066] The purified RBD-SD was mixed with SD-CD40L, ICOS-SD, and IL-21-SD monomers in a molar ratio of 1:1; then the obtained products were incubated with Gvo-HPF in Tris-NaCl buffer at room temperature overnight for self-assembly to prepare nanoparticles (RBD NP, ICOS-RBD NP, IL-21-RBD NP, and CD40L-RBD NP), respectively.
[0067] The incubated product was concentrated by ultrafiltration, and then the protein concentration was tested using a BCA protein concentration assay kit, followed by Coomassie brilliant blue staining to detect the coupling of nanoparticles.
[0068] The purity and uniformity of the nanoparticles were characterized by transmission electron microscopy (TEM).
[0069] 2. Experimental Results
[0070] The identification results of each target protein and each nanoparticle Coomassie Brilliant Blue staining are shown in Figure 1 B in the figure, the results of SEM analysis are shown in Figure 1 C in the figure shows that the self-assembled nanoparticles were of uniform size. The particles were polyhedral spheres, and RBD, CD40L, ICOS and IL-21 were all displayed in the form of spikes on the surface of the HPF nanoparticles, successfully preparing the new coronavirus nanoparticle vaccine.
[0071] Example 2 Immune response of novel coronavirus nanoparticle vaccine under immune deficiency conditions
[0072] 1. Experimental Methods
[0073] Used CD4 cre Bcl6 fl / fl Mouse (Kristin Hollister, et al. Insights into the Role of Bcl6 in Follicular Th Cells Using a New Conditional Mutant Mouse Model, JImmunol (2013) 191 (7): 3705-3711. https: / / doi.org / 10.4049 / jimmunol.1300378), in which the T cells of the mouse cannot differentiate into T cells due to the knockout of the Bcl6 gene. FH Cells are unable to form germinal centers in vivo and their antibody production capacity is impaired, so they are used to simulate immunodeficiency conditions.
[0074] After the target protein was concentrated, mice were immunized with RBD NP, ICOS-RBD NP, IL-21-RBD NP and CD40L-RBD NP prepared in Example 1. Each group was diluted to 100 μl with 20 mM Tri-HCl 50 mM NaCl, pH = 7.5, and emulsified with an equal volume of Alum adjuvant. 10 μg RBD equivalent was injected per mouse. Then, CD4 cre Bcl6 fl / flMice were immunized in groups. Each mouse was subcutaneously injected with a 200 μl inoculation volume. A booster injection was performed on the 14th day. On the 14th and 28th days after the primary immunization, blood was collected from the mice’s eye sockets. After the mouse serum was allowed to stand for a period of time to precipitate, it was centrifuged at 4°C, 2800 rpm for 15 minutes and used for the Anti-RBD IgG ELISA test. See the procedure for details. Figure 2 A in.
[0075] 2. Experimental Results
[0076] The results are as follows Figure 2 The results showed that 2 weeks after Prime / Boost immunization, the RBD-specific IgG levels in the CD40L-RBD NP immunization group, ICOS-RBD NP immunization group, and IL-21-RBD NP immunization group increased by 9.4 times, 63 times, and 13 times, respectively, compared with the RBD NP immunization group. Figure 2 B). The RBD-specific IgA titer in the ICOS-RBD NP immunization group was 18-fold or 9-fold higher than that in the CD40L-RBD NP immunization group and the IL-21-RBD NP immunization group, respectively. IgA levels are directly related to mucosal immunity against infection ( Figure 2 C). The ICOS-RBD NP immunization group also showed the highest RBD-specific IgG antibody titer in the long-term observation ( Figure 2 The above results show that ICOS-coupled nanoparticles can significantly enhance the efficacy of SARS-CoV-2 RBD nanoparticle vaccines in T FH Antibody responses in β-deficient mice.
[0077] Example 3 Affinity and neutralizing activity of antibodies produced by novel coronavirus nanoparticle vaccines
[0078] 1. Experimental Methods
[0079] 1. Detection of the content ratio of high affinity antibodies
[0080] The serum of the immunized mice 6 weeks after the primary immunization in Example 2 was tested for antigen-specific antibody titer by ELISA. During the detection process, 7M urea concentration was added for elution. The antibodies that could be washed away were low-affinity antibodies, and the antibodies that could still bind to the plate after 7M urea treatment were high-affinity antibodies. By comparing the ELISA readings of 7M urea treatment and untreated, the content ratio of high-affinity antibodies was calculated.
[0081] Specifically, the ELISA plate was coated with 5 μg / ml SARS-CoV-2RBD antigen protein in 0.1M bicarbonate buffer (pH 9.3) at 4°C overnight. After washing three times with PBS, it was blocked with 5% skim milk / PBS at room temperature for 1 hour. It was washed three times with PBST (containing 1% Tween-20) again, and the animal serum of each group of mice in Example 2 was serially diluted in PBS, and then the plate was incubated at 37°C for 1 hour. After incubation of the diluted serum, the plate was washed twice with PBST. The wells were incubated with PBST or PBST (containing 7M urea) at room temperature for 10 minutes. After washing with PBST, a 1:4000 dilution of HRP-labeled goat anti-mouse IgG was added to detect antigen-specific antibodies in mouse serum. After incubation for another 1 hour, the plate was washed with PBST. Subsequently, 50 μL of HRP substrate TMB solution (eBioscience) was added to each well, reacted in the dark, and the reaction was terminated with a stop solution (Solarbio) after the reaction was fully developed. Absorbance was measured at 450 nm. Data were analyzed by nonlinear regression using GraphPad Prism 9.0 software to calculate endpoint titers. The affinity index for each serum sample was calculated by dividing the readings from the PBST (containing 7 M urea) incubation by the readings from the PBST incubation alone.
[0082] 2. SARS-CoV-2 pseudovirus neutralizing antibody test
[0083] The SARS-CoV-2 Spike protein was inserted into the pcDNA3.1 expression vector using a pseudovirus system based on a lentiviral vector (Ma X, Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses. Immunity. 2020 Dec 15; 53(6): 1315-1330.e9.doi:10.1016 / j.immuni.2020.11.015. Epub 2020 Nov 25. PMID: 33275896 Free PMC article.) to obtain an expression vector for the SARS-CoV-2 Spike protein.
[0084] The expression vector of SARS-CoV-2Spike protein was co-transfected with pHIV-luciferase and psPAX2 plasmids into 293T cells. After 5 hours of transfection, the cells were washed twice with PBS and then switched to serum-free DMEM medium for continued culture. After 48 hours, the supernatant was collected, centrifuged to remove cell debris, and dissolved in a small volume of serum-free DMEM to obtain HIV-luc / SARS-CoV-2-S pseudovirus.
[0085] The HIV-luc / SARS-CoV-2-S pseudovirus can effectively simulate the process of wild-type SARS-CoV-2 invading cells. When it infects production cells or target cells, the expression of the luciferase reporter gene it carries can accurately reflect the results of viral infection, so that the results of the experimental system can be read accurately and quickly, and it can be used as an excellent antibody neutralization titer monitoring system.
[0086] The serum of the immunized mice was allowed to stand at room temperature for a period of time until the serum precipitated, and then the antibody serum was obtained by centrifugation at 4°C and 2800rpm for 15 minutes. The obtained antibody serum was diluted 2-fold, mixed with HIV-luc / SARS-CoV-2-S pseudovirus, and incubated at 37°C for 1 hour. The mixture was added to a 96-well plate in hACE2-HEK293T cells with a density of about 70%. After 48 hours, the culture medium was discarded, washed twice with PBS, and cell lysate was added to detect the luciferase activity value. Among them, compared with the luciferase activity value of the group without virus addition, the dilution concentration at which the antibody serum inhibited 50% was the pVNT50 result.
[0087] 2. Experimental Results
[0088] result Figure 3 As shown, the high-affinity antibodies in the ICOS-RBD NP immunization group increased by 46% compared with the RBD NP immunization group ( Figure 3 A in the figure). In the SARS-CoV-2 pseudovirus neutralizing antibody test, the titer of nAb induced by ICOS-RBDNP immunization was 38 times and 32 times higher than that of CD40L-RBD NP and IL-21-RBD NP, respectively ( Figure 3 (B) These results suggest that, in the setting of immunodeficiency, conjugated ICOS enhanced the production of high-quality antibodies induced by SARS-CoV-2 RBD nanoparticle vaccine immunization.
[0089] Example 4 ICOS significantly enhances B cell responses
[0090] 1. Experimental Methods
[0091] CD4CreBcl6fl / fl mice were immunized with the RBD NP and ICOS-RBD NP prepared in Example 1, and 14 days later, the percentage and number of total T cells in the lymph nodes of CD4CreBcl6fl / fl mice in the ICOS-RBD NP immunization group and the RBD NP immunization group were detected. The specific detection method is: after the target protein is concentrated, mice are immunized according to the equivalent of 10 μg of RBD protein.
[0092] RBD NP or ICOS-RBD NP was diluted to 100 μl with pH 7.5 Tris-NaCl buffer and emulsified with an equal volume of Alum adjuvant. cre Bcl6 fl / fl Mice were immunized in groups. Each mouse was inoculated with 200 μl of vaccine by subcutaneous injection. On the 14th day after immunization, spleen, lymph nodes, and bone marrow cells of mice were obtained for flow cytometric antibody staining to analyze mouse T cells (CD3+), B cells (B220+), and B cell memory cells (IgD-CD38+), plasmablast subsets (B220+CD138+), respectively.
[0093] 2. Experimental Results
[0094] Immunization of CD4 with RBD NP and ICOS-RBD NP Cre Bcl6 fl / fl Mice, 14 days later, there was no significant difference in the percentage and number of total T cells in lymph nodes between the ICOS-RBD NP immunization group and the RBD NP immunization group ( Figure 4 However, the percentage of B cells in the lymph nodes of the ICOS-RBD NP-immunized group increased by 37% and the number of B cells increased by 48% ( Figure 4 A and
[0095] C), which indicates that ICOS directly affects the proliferation of B cells. Although there was no significant change in the germinal center B (GCB) cells in the spleen of mice immunized with ICOS-RBD NP ( Figure 4 D), the percentage and number of plasmablasts in the ICOS-RBD NP immunization group increased by 53% and 76%, respectively ( Figure 4 E), plasmablasts secrete antibodies and are associated with long-lived plasma cells in the bone marrow, providing support for long-term protection. In addition, the number of B cells in the spleen of the ICOS-RBD NP immunization group increased by 82% compared with the RBD NP immunization group ( Figure 4 F), the number of memory B cells (MBC) increased by 1.5 times compared with the RBD NP immunization group ( Figure 4 G in.
[0096] In T FH In the absence of cells, RBD NP alone could hardly induce the production of antibody secreting B cells (ASCs) after immunization. However, ICOS-RBD NP significantly increased the number of RBD-specific ASCs ( Figure 4 These results show that ICOS FH B cell responses, particularly the production of antibody-secreting cells, were significantly enhanced in KO mice.
[0097] Example 5 Binding of ICOS protein to ICOSL protein
[0098] 1. Experimental Methods
[0099] To further determine the correlation between the binding of ICOS and ICOSL and the activation and proliferation of stimulated B cells, anti-ICOSL blocking antibody was used to pre-treat CD4 Cre Bcl6 fl / fl The mice were immunized for 24 hours and then immunized with the RBD-ICOS NP prepared in Example 1. The dose was equivalent to 10 μg of RBD protein. After 14 days of immunization, the mouse serum was separated for antigen-specific antibody titer ELISA analysis.
[0100] Among them, anti-ICOSL blocking antibody, 500μg / mouse (Biolegend clone HK5.3 Catlog 107412) (PMID: J Immunol 12960306, PNAS15014176)
[0101] 2. Experimental Results
[0102] Flow cytometry showed that purified ICOS protein binds to ICOSL on B cells ( Figure 5 A in Figure 1). 14 days after immunization, the results showed that ICOSL blocking significantly inhibited the production of SARS-CoV-2 RBD-specific IgG antibodies induced by ICOS-RBD nanoparticles compared with the unblocked group ( Figure 5 In addition, ICOSL blockade also reduced ICOS-RBD nanoparticle-induced plasmablasts (B220 + CD138 + )percentage( Figure 5 C), which shows that ICOS-RBD nanoparticles can be FH In the case of cells, immune responses were enhanced through ICOSL on B cells.
[0103] Example 6 ICOS can promote the survival and proliferation of primary B cells in vitro
[0104] 1. Experimental Methods
[0105] Direct treatment of CD4 with ICOS NP or HPF NP in vitro Cre Bcl6 fl / fl Mouse spleen isolation B cells.
[0106] Then, ICOS NP, CD40L NP, IL21 NP, and HPF NP were directly used to separate the NPs from the spleen of mice. B cells were co-cultured. After 48 hours, some cells were stained with anti-Annexin V and PI, and cell apoptosis was analyzed by flow cytometry; some cells were incubated with BrdU for 2 hours, stained with anti-BrdU and DAPI, and cell cycle was analyzed by flow cytometry.
[0107] The preparation method of HPF NP is as follows: the Gvo-HPF prepared in Example 1 is incubated in Tris-NaCl buffer at room temperature overnight to perform self-assembly;
[0108] The preparation method of CD40L NP is as follows: the SD-CD40L prepared in Example 1 is incubated with Gvo-HPF in Tris-NaCl buffer at room temperature overnight to obtain self-assembly;
[0109] The preparation method of IL21 NP is as follows: the IL-21-SD prepared in Example 1 is incubated with Gvo-HPF in Tris-NaCl buffer at room temperature overnight to obtain self-assembly;
[0110] The preparation method of ICOS NP is as follows: the ICOS-SD prepared in Example 1 is incubated with Gvo-HPF in Tris-NaCl buffer at room temperature overnight to obtain ICOS NP by self-assembly.
[0111] 2. Experimental Results
[0112] Compared with HPF NP treatment, ICOS NP can significantly enhance the proliferation of mouse primary B cells in vitro ( Figure 6 A and B in ).
[0113] Cell cycle analysis showed that ICOS NP promoted the advancement of B cells from G1 phase to S phase, and the proportion of S phase was 6 times higher than that of HPF NP group or IL-21NP group ( Figure 6 C). In the control group treated with HPF NP, the survival rate of B cells was only 35%, while that of B cells in the ICOS group exceeded 50% ( Figure 6 D).
[0114] This shows that ICOS can promote the survival and proliferation of primary B cells in vitro.
[0115] Example 7 ICOS activates ICOSL to promote B cell proliferation and anti-apoptosis
[0116] 1. Experimental Methods
[0117] 1. Western Blot analysis of key proteins related to B cell proliferation
[0118] Mouse spleen B cells were separated by anti-CD19 magnetic beads, and then directly co-cultured with B cells with 50 μg / mL concentration of ICOSNP, CD40L NP and IL21 NP, respectively. After 48 hours, some cells were stained with anti-AnnexinV and PI, and cell apoptosis was analyzed by flow cytometry; some cells were incubated with BrdU for 2 hours, stained with anti-BrdU and DAPI, and the cell cycle was analyzed by flow cytometry; some cells were lysed with Trizol to extract RNA, and the mRNA was reversed into cDNA for mRNA qPCR quantitative detection of related genes; some cells were lysed with RIPA to extract protein, and SDS-PAGE separation and Western Blot analysis of related antibodies were performed.
[0119] The preparation methods of ICOS NP, CD40L NP and IL21 NP were the same as those in Example 6.
[0120] 2. Experimental Results
[0121] The results showed that the phosphorylation levels of PKC, AKT, NF-κB and other proteins in B cells were significantly increased after ICOS NP treatment ( Figure 7 At the same time, qPCR was also used to detect the expression of cell cycle-related genes, showing that the expression of Ccna2, Ccnd1, and Cdk4 was increased in B cells treated with ICOS NP ( Figure 7 In particular, ICOS NP treatment increased the expression of the anti-apoptotic gene Mcl1 in B cells ( Figure 7 B) shows that ICOS NP can promote cell cycle and maintain cell survival phenotype.
[0122] Example 8 Protective ability of the novel coronavirus ICOS-RBD nanoparticle vaccine on immunodeficient mice
[0123] The Beta, Delta, or Omicron subtypes of the novel coronavirus can directly infect wild-type mice due to the N501Y mutation on the Spike, which increases the affinity for mouse ACE2. It can also directly infect CD4 Cre Bcl6 fl / fl Mouse.
[0124] 1. Experimental Methods
[0125] To evaluate the effects of ICOS-carrying nanoparticles on CD4 Cre Bcl6 fl / fl HPF, RBD and ICOS-RBD nanoparticle vaccines were used to immunize mice twice in a prime-boost manner, with subcutaneous immunization of CD4 Cre Bcl6 fl / fl Mice were immunized for 4 weeks, and the serum of mice was tested by ELISA at 4 weeks after immunization. Then, the SARS-CoV-2 Omicron EG.5 strain was intranasally infected, and the mice were euthanized on the 5th day after virus infection. The lungs of the mice were lysed with Trizol to extract total RNA, and the viral mRNA copy number was analyzed using the new coronavirus mRNA detection kit. The lungs of the mice were taken for H&E staining and IHC staining with anti-SARS-CoV-2N protein antibody ( Figure 8 A).
[0126] 2. Experimental Results
[0127] The results are as follows Figure 7 The results showed that the ICOS-RBD nanoparticle vaccine group produced higher RBD-specific IgG antibody titers than the HPF and RBD groups ( Figure 8 (B) After mice were infected with Omicron EG.5, the average viral RNA in the lungs of HPF mice was 9.02×10 per μg of total RNA. 6 However, the ICOS-RBD nanoparticle vaccine group reduced viral replication by approximately 1660 or 10-fold compared with the HPF or RBD nanoparticle vaccine groups ( Figure 8 C).
[0128] H&E staining showed that the lungs of mice immunized with ICOS-RBD vaccine had significantly less inflammation than those in other groups ( Figure 8 D).
[0129] At the same time, in the lungs of ICOS-RBD-immunized mice, the expression of SARS-CoV-2 nucleocapsid (N) antigen was always the lowest ( Figure 8 E).
[0130] In summary, ICOS-RBD NP induced a significant immune response and effectively suppressed CD4Cre Bcl6 fl / fl SARS-CoV-2 infection of mice.
[0131] Example 9 Preparation of HIV Nanoparticle Vaccine
[0132] 1. Experimental Methods
[0133] Because in HIV-1 infected patients, the virus directly infects CD 4+ T cells and can also damage T FH The cells cause serious immune deficiency / insufficiency, so the antibody levels of HIV patients after vaccination are seriously reduced compared with healthy people.
[0134] The MD39 immunogen contains the N332 supersite epitope in the V3 loop of the HIV-1 gp120 outer membrane, which can be used to induce broad-spectrum neutralizing antibodies against HIV. HIV-1 MD39 was selected as a model antigen to prepare nanoparticle vaccines and coupled with ICOS ( Fig. 9 A in the figure is its schematic diagram), in order to evaluate the effect of coupled ICOS on the immune effect of HIV vaccine.
[0135] The ICOS-MD39 nanoparticle vaccine and the MD39 nanoparticle vaccine were constructed as follows:
[0136] The pcDNA3.1-MD39-SD-His eukaryotic expression plasmid (Steichen, J.M. et al. HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. Immunity 45, 483-496, doi: 10.1016 / j.immuni.2016.08.016(2016)) was constructed according to the method of Example 1 (wherein the nucleotide sequence of MD39-SD-His is shown in SEQ ID NO: 17, and the amino acid sequence encoded by it is shown in SEQ ID NO: NO: 18), and transiently transfected into HEK293F cells. After 5 days of transfection, the cell supernatant was collected; then MD39-SD-His and ICOS-SD-His (prepared in Example 1) were coupled to Gvo-HPF nanoparticles together according to the method of Example 1, and then Coomassie Brilliant Blue staining and protein immunoblotting were used to detect the expression of the above-mentioned target proteins and the assembly of HIV-1 nanoparticle vaccine.
[0137] 2. Experimental Results
[0138] The results are as follows Fig. 9B to C in the figure show that the nanoparticle vaccine (ICOS-MD39NP and MD39 NP) against HIV was successfully assembled.
[0139] Example 10 Immune effect of HIV nanoparticle vaccine on immunodeficient mice
[0140] 1. Experimental Methods
[0141] ICOS-MD39 NP and MD39 NP prepared in Example 9 were immunized against CD4 Cre Bcl6 fl / fl Mice, detection of HIV-1 antigen-specific serum IgG titer, urea-eluted high-affinity antibody titer, and Elispot analysis of HIV-1 antigen-specific antibody secreting cell number, Fig. 9 D in is a flow chart.
[0142] 2. Experimental Results
[0143] The results showed that the levels of HIV Env-specific IgG and high-affinity antibodies in the ICOS-MD39 immunization group were significantly higher than those in the MD39 immunization group alone and could be maintained for several weeks ( Fig. 9 E to G in Figure 3). ELISpot assay showed that the number of HIVEnv antigen-specific antibody-secreting cells increased significantly 8 weeks after immunization.
[0144] The above results indicate that ICOS can also enhance antibody production and the number of antibody-secreting cells of HIV nanoparticle vaccines under immunodeficient conditions, which is beneficial for vaccines in HIV-infected patients.
Claims
1. Use of ICOSL protein agonists in the preparation of vaccines or vaccine adjuvants.
2. Use of ICOSL protein agonists in the preparation of vaccines or enhancers of vaccine adjuvants.
3. The use according to claim 1 or 2, characterized in that: The agonist of ICOSL protein is ICOS protein.
4. A vaccine or adjuvant comprising an agonist of ICOSL protein.
5. Application of ICOSL protein agonist and antigen composition in vaccine preparation.
6. An antigen with enhanced immunogenicity, characterized in that: The antigen is obtained by spontaneous chemical bonding of component 1 and component 2 through Gv-Sd, wherein component 1 is a mixture of a protein having an amino acid sequence such as SEQ ID NO: 12 and a fusion protein containing an immunogen, wherein the fusion protein containing the immunogen is a protein expressed by fusion of an immunogen and a SD peptide segment, and the amino acid sequence of the SD peptide segment is shown in SEQ ID NO: 8; and component 2 is a protein having an amino acid sequence such as SEQ ID NO:
5.
7. An antigen of a novel coronavirus with enhanced immunogenicity, characterized in that: The antigen is obtained by combining component 1 and component 2 through spontaneous chemical bonds of Gv-Sd, wherein component 1 is a mixture of a protein with an amino acid sequence such as SEQ ID NO: 12 and a protein with an amino acid sequence such as SEQ ID NO: 9; and component 2 is a protein with an amino acid sequence such as SEQ ID NO:
5.
8. An HIV virus antigen with enhanced immunogenicity, characterized in that: The antigen is obtained by combining component 1 and component 2 through spontaneous chemical bonds of Gv-Sd, wherein component 1 is a mixture of a protein with an amino acid sequence such as SEQ ID NO: 12 and a protein with an amino acid sequence such as SEQ ID NO: 18; and component 2 is a protein with an amino acid sequence such as SEQ ID NO:
5.
9. Use of the antigen according to any one of claims 5 to 7 in the preparation of a vaccine.
10. A vaccine with enhanced immunogenicity, characterized in that: The vaccine is prepared using the antigen described in any one of claims 5 to 7.
Citation Information
Patent Citations
Compositions and methods for vaccination and treatment of infectious diseases
CN115916821A
Method for enhancing broad spectrum of new crown mutant strain vaccine and new crown broad-spectrum vaccine
CN116041540A
Methods for treating covid-19 based on individual genomic profiles
US20220323573A1
Cited By
Adjuvant and application thereof in vaccine preparation
CN119504957A
